PE20180036A1 - Inhibidores de bromodominio - Google Patents

Inhibidores de bromodominio

Info

Publication number
PE20180036A1
PE20180036A1 PE2017002306A PE2017002306A PE20180036A1 PE 20180036 A1 PE20180036 A1 PE 20180036A1 PE 2017002306 A PE2017002306 A PE 2017002306A PE 2017002306 A PE2017002306 A PE 2017002306A PE 20180036 A1 PE20180036 A1 PE 20180036A1
Authority
PE
Peru
Prior art keywords
methylisoquinolin
methylsulfonylphenyl
cyclopropylmethoxy
pharmaceutical composition
bromodominium
Prior art date
Application number
PE2017002306A
Other languages
English (en)
Inventor
Juan Manuel Betancort
Jeffrey Alan Stafford
Ryan Stansfield
James Marvin Veal
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of PE20180036A1 publication Critical patent/PE20180036A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Referida a una composicion farmaceutica que comprende la forma cristalina A de 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona. En algunas realizaciones, la composicion farmaceutica comprende 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona que se ha procesado por micronizacion o dispersion secada por pulverizacion. En algunas realizaciones, la composicion farmaceutica comprende ademas al menos un polimero. En algunas realizaciones, las composiciones farmaceuticas comprenden una matriz polimerica solida que comprende 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona y al menos un polimero. Dichas composiciones farmaceuticas son utiles para el tratamiento del cancer o enfermedades neoplasicas
PE2017002306A 2015-04-22 2016-04-22 Inhibidores de bromodominio PE20180036A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562151205P 2015-04-22 2015-04-22

Publications (1)

Publication Number Publication Date
PE20180036A1 true PE20180036A1 (es) 2018-01-09

Family

ID=57143581

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002306A PE20180036A1 (es) 2015-04-22 2016-04-22 Inhibidores de bromodominio

Country Status (23)

Country Link
US (1) US20160310423A1 (es)
EP (1) EP3285770A4 (es)
JP (1) JP2018513863A (es)
KR (1) KR20170139119A (es)
CN (1) CN107613981A (es)
AR (1) AR104340A1 (es)
AU (1) AU2016252992A1 (es)
BR (1) BR112017022691A2 (es)
CA (1) CA2983446C (es)
CL (1) CL2017002679A1 (es)
CO (1) CO2017011482A2 (es)
EA (1) EA201792317A1 (es)
EC (1) ECSP17071545A (es)
HK (1) HK1243948A1 (es)
IL (1) IL255120B (es)
MX (2) MX2017013501A (es)
NZ (1) NZ736630A (es)
PE (1) PE20180036A1 (es)
PH (1) PH12017501933A1 (es)
SG (1) SG11201708627TA (es)
TW (1) TW201642860A (es)
WO (1) WO2016172618A1 (es)
ZA (1) ZA201707186B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN110099685A (zh) * 2016-10-20 2019-08-06 赛尔基因光迪斯研究公司 溴结构域抑制剂
CA3041049A1 (en) 2016-10-27 2018-05-03 Celgene Quanticel Research, Inc. Bromodomain and extra-terminal protein inhibitor combination therapy
AU2019309693B2 (en) * 2018-07-23 2023-03-16 Celgene Quanticel Research, Inc. Process for the preparation of bromodomain inhibitor
EP4294397A1 (en) * 2021-02-22 2023-12-27 Celgene Quanticel Research, Inc. Bromodomain (bet) inhibitor for use in treating prostate cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
PL3640241T3 (pl) * 2013-10-18 2022-12-05 Celgene Quanticel Research, Inc. Inhibitory bromodomeny
CN110099685A (zh) * 2016-10-20 2019-08-06 赛尔基因光迪斯研究公司 溴结构域抑制剂

Also Published As

Publication number Publication date
ZA201707186B (en) 2019-01-30
TW201642860A (zh) 2016-12-16
NZ736630A (en) 2024-03-22
SG11201708627TA (en) 2017-11-29
KR20170139119A (ko) 2017-12-18
EP3285770A1 (en) 2018-02-28
IL255120B (en) 2021-03-25
IL255120A0 (en) 2017-12-31
JP2018513863A (ja) 2018-05-31
WO2016172618A1 (en) 2016-10-27
HK1243948A1 (zh) 2018-07-27
CL2017002679A1 (es) 2018-05-25
ECSP17071545A (es) 2017-12-01
EP3285770A4 (en) 2018-10-31
MX2020010899A (es) 2022-02-15
CN107613981A (zh) 2018-01-19
AU2016252992A1 (en) 2017-11-09
PH12017501933A1 (en) 2018-03-19
CA2983446C (en) 2024-04-09
US20160310423A1 (en) 2016-10-27
MX2017013501A (es) 2018-02-09
CO2017011482A2 (es) 2018-01-31
AR104340A1 (es) 2017-07-12
EA201792317A1 (ru) 2018-03-30
CA2983446A1 (en) 2016-10-27
BR112017022691A2 (pt) 2018-07-17

Similar Documents

Publication Publication Date Title
PE20180036A1 (es) Inhibidores de bromodominio
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
CL2018001230A1 (es) Tratamiento de osteoartritis
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2017001040A1 (es) Métodos para tratar infecciones por el virus filoviridae
AR102657A1 (es) Composición para tratar telas
CU20170089A7 (es) Derivados de quinazolina utilizados para tratar el vih
ECSP17026210A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
BR112017003705A2 (pt) compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
CL2018001092A1 (es) Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, métodos su elaboración y métodos para sus uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histamínico.
PE20171646A1 (es) Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
CR20160016A (es) Pirazolpiridinas sustituidas
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
BR112016017776A2 (pt) Formas sólidas de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidróxi-4-metil-ciclo-hexilamino)-pirimidina-5-carboxamida, composições das mesmas e métodos para seu uso
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
BR112018009745A8 (pt) compostos heterocíclicos para o tratamento de doença
AR109859A1 (es) Inhibidor de bromodominio
CL2017002229A1 (es) Inhibidores de bace1.
BR112017028185A2 (pt) composições farmacêuticas sólidas para tratar hcv

Legal Events

Date Code Title Description
FA Abandonment or withdrawal